Showing 2261-2270 of 3315 results for "".
- New Data Suggest Uplinza for the Treatment of NMOSD Did Not Increase the Risk of COVID-19 or Reduce Antibody Levels From Childhood Vaccineshttps://modernod.com/news/new-data-suggest-uplinza-for-the-treatment-of-nmosd-did-not-increase-the-risk-of-covid-19-or-reduce-antibody-levels-from-childhood-vaccines/2481438/Horizon Therapeutics announced new data suggest Uplinza does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies. Uplinza is the first and only B-cell-depleting monotherapy approved by the FDA and the European Commission for the tre
- Clearside Biomedical Announces Leadership Changeshttps://modernod.com/news/clearside-biomedical-announces-leadership-changes/2481386/Clearside Biomedical announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, MD, will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ci
- New UCI-Led Study Shows Repeated Stress Accelerates Aging of the Eyehttps://modernod.com/news/new-uci-led-study-shows-repeated-stress-accelerates-aging-of-the-eye/2481260/New research from the University of California, Irvine, suggests aging is an important component of retinal ganglion cell death in glaucoma, and that novel pathways can be targeted when designing new treatments for glaucoma patients. The study, titled, “
- Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 for Retinal Diseaseshttps://modernod.com/news/kinarus-receives-uspto-notice-of-allowance-for-lead-therapeutic-candidate-kin001-for-retinal-diseases/2481256/Kinarus Therapeutics announced the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 16/500,504 “Methods of preventing or treating Ophthalmic Diseases" covering its therapeutic candidate KIN001 in age-relat
- Lumata Health Raises $4 Million in Series A Funding to Scale its Human-Led, Intelligent Eye Care Management Platformhttps://modernod.com/news/lumata-health-raises-4-million-in-series-a-funding-to-scale-its-human-led-intelligent-eye-care-management-platform/2481201/Lumata Health announces $4 million in new venture funding to scale its impact throughout the United States. Lumata Health currently serves thousands of patients suffering from vision-threatening chronic eye conditions through partnerships with ophthalmology clinics and h
- Alcon to Celebrate 75 Years and Showcase Contact Lens Innovations at #Academy22https://modernod.com/news/alcon-to-celebrate-75-years-and-showcase-contact-lens-innovations-at-academy22/2481197/Alcon will feature a host of innovations across its portfolio of products along with pertinent practice takeaways at the American Academy of Optometry Annual Meeting (#Academy22) in San Diego, California, on October 27, 2022. The meeting coincides with Alcon’s Diamond Jubilee, celebrating 7
- Study: Specialized Smart Soft Contact Lenses Can Address Global Issue of Glaucoma Diagnosis, Managementhttps://modernod.com/news/study-specialized-smart-soft-contact-lenses-can-address-global-issue-of-glaucoma-diagnosis-management/2481144/The vision of
- CooperVision Appoints Weiwen Chen to Lead Asia-Pacific Region Expansionhttps://modernod.com/news/coopervision-appoints-weiwen-chen-to-lead-asia-pacific-region-expansion/2481114/
- High-Tech Imaging Reveals Details About Rare Eye Disorderhttps://modernod.com/news/high-tech-imaging-reveals-details-about-rare-eye-disorder/2481022/Using a new imaging technique, researchers from the National Eye Institute (NEI) have determined that retinal lesions from vitelliform macular dystrophy (VMD) vary by gene mutation. Addressing these differences may be key in designing effective treatments for this and other rare diseases, accordi
- AcuFocus Receives FDA Approval for the IC-8 Apthera IOL, the First and Only Small Aperture Lenshttps://modernod.com/news/acufocus-announces-fda-approval-for-the-ic-8-apthera-iol-the-first-and-only-small-aperture-lens-for-cataract-surgery/2480986/AcuFocus has received FDA approval for its IC-8 Apthera IOL, the first and only non-toric extended depth-of-focus IOL approved for the 82% of cataract patients who have as much as 1.5 diopters (D) of corneal astigmatism.2 “We are delighted to receive